RxDoctor Payments DataLook up a doctor →

Roger Lidman, MD

Rheumatology · Chesapeake, VANPI 1639150881

Payments from drug & device makers

$118,195in general payments, 2019–2025

Across 908 payments — averaging $130.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$34K
  • Eli Lilly$33K
  • AbbVie$19K
  • Gilead$13K
  • Janssen Research & Development, LLC$5K
  • Amgen$4K
  • plus $11K from 36 others
$2,724in research payments, 2019–2025

Across 1 payment — averaging $2724.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$3K

What the payments were for

  • Food & beverage$15,76298%
  • Education$2872%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$118,195 in reported general payments places this provider in the 90th percentile of 159 rheumatology providers in Virginia.

See all rheumatology providers in Virginia

Medicare billing

Part B allowed, 2024
$2,689,684
Medicare patients
736
Services billed
197,751

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ActharCorticotropin14$1,201,638
RinvoqUpadacitinib48$412,041
Humira(Cf) PenAdalimumab11$304,401
XeljanzTofacitinib Citrate38$258,913
EnbrelEtanercept34$246,114
Enbrel SureclickEtanercept21$148,695
Xeljanz XrTofacitinib Citrate14$88,301
Orencia ClickjectAbatacept13$72,763
OtezlaApremilast11$54,982
Teriparatide17$32,246
Hydroxychloroquine Sulfate100$4,746
MethotrexateMethotrexate Sodium167$3,739
Celecoxib43$3,134
Prednisone366$2,934
Colchicine39$2,604

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Mallinckrodt Hospital Products Inc.Acthar$499$1,201,63814 claims
AbbVieRinvoq$19,038$412,04148 claims
AmgenEnbrel, Otezla$3,549$301,09545 claims
PfizerXeljanz$34,382$258,91338 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 159 rheumatology providers in Virginia.

Other rheumatology in Chesapeake

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →